Utility of metformin as an adjunct to hydroxycitrate/carnitine for reducing body fat in diabetics

Medical Hypotheses

Volumn 51, Issue 5, 1998, Pages 399-403

  McCarty, M F ^a  

^a Nutrition 21 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE; HYDROXYCITRIC ACID; METFORMIN;

ARTICLE; BODY FAT; CARDIOVASCULAR RISK; DIABETES MELLITUS; FAT INTAKE; FATTY ACID OXIDATION; GLUCONEOGENESIS; HUMAN; OBESITY; PRIORITY JOURNAL; THERMOGENESIS; WEIGHT REDUCTION;

EID: 0031766162     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(98)90035-4     Document Type: Article

References (78)

1. McGarry J D. What if Minkowski had been ageusic? An alternative angle on diabetes. Science 1992; 258: 766-770.
2. Paolisso G, Tataranni P A, Foley J E et al. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetiologia 1995; 38: 1213-1217.
3. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1996; 45: 3-10.
4. Fraze E, Donner C C, Swislocki A L M et al. Ambient plasma free fatty acid concentrations in noninsulin-dependent diabetes mellitus: evidence for insulin resistance. J Clin Endocrinol Metab 1985; 61: 807-811.
5. Chen Y-DI, Golay A, Swislocki A L M, Reaven G M. Resistance to insulin suppression of plasma free fatty acid concentrations and insulin stimulation of glucose uptake in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1987; 64: 17-21.
6. Reaven G M, Hollenbeck C, Jeng C Y et al. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 1988; 37: 1020-1024.
7. Foley J E. Mechanisms of impaired insulin action in isolated adipocytes from obese and diabetic subjects. Diab/Metab Rev 1988; 4: 487-505.
8. Björntorp P. 'Portal' adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990; 10: 493-496.
9. Falholt K, Jensen I, Jensen S L et al. Carbohydrate and lipid metabolism of skeletal muscle in type 2 diabetic patients. Diabetic Med 1988; 5: 27-31.
10. Maggs D G, Jacob R, Rife F et al. Interstitial fluid concentrations of glycerol, glucose, and amino acids in human quadricep muscle and adipose tissue. J Clin Invest 1995; 96: 370-377.
11. Storlien L H, Jenkins A B, Chisholm D J et al. Influence of dietary fat composition on development of insulin resistance in rats. Relationship to muscle triglyceride and ω̧ -3 fatty acids in muscle phospholipid. Diabetes 1991; 40: 280-289.
12. Björntorp P. Metabolic implications of body fat distribution. Diabetes Care 1991; 14: 1132-1143.
13. Bolinder J, Kager L, Östman J, Arner P. Differences at the receptor and postreceptor levels between human omental and subcutaneous adipose tissue in the action of insulin on lipolysis. Diabetes 1983; 32: 117-123.
14. Hotamisligil G S, Arner P, Caro J F et al. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-2415.
15. Kern P A, Saghizadeh M, Ong J M et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95: 2111-2119.
16. Schmitz-Peiffer C, Browne C L, Oakes N D et al. Alterations in the expression and cellular localization of protein kinase C isozymes ∈ and θ are associated with insulin resistance in skeletal muscle of the high-fat-fed rat. Diabetes 1997; 46: 169-178.
17. Ferrannini E, Barret E J, Bevilacqua S, DeFronzo R A. Effect of fatty acids on glucose production and utilization in man. J Clin Invest 1983; 72: 1737-1747.
18. Rebrin K, Steil G M, Getty L, Bergman R N. Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin. Diabetes 1995; 44: 1038-1045.
19. Rebrin K, Steil G M, Mittelman S D, Bergman R N. Causal linkage between insulin suppression of lipolysis and suppression of liver glucose output in dogs. J Clin Invest 1996; 98: 741-749.
20. Lee Y, Hirose H, Ohneda M et al. β-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats impairment in adipocyte - β-cell relationships. Proc Natl Acad Sci 1994; 91:10878-10882.
21. Unger R H. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications. Diabetes 1995; 44: 863-870.
22. Thorens B, Wu Y-J, Leahy J L, Weir G C. The loss of GLUT2 expression by glucose-unresponsive, β cells of db/db mice is reversible and is induced by the diabetic environment. J Clin Invest 1992; 90: 77-85.
23. Steinberg H, Learning R, Cronin J et al. Elevated free fatty acids (FFA) levels impair endothelium dependent vasodilation. Diabetes 1996; 45(Suppl. 2): 11A.
24. McCarty M F. Reduction of free fatty acids may ameliorate risk factors associated with abdominal obesity. Med Hypotheses 1995; 44: 278-286.
25. Donnelly R, Reed M J, Azhar S, Reaven G M. Expression of the major isoenzyme of protein kinase-C in skeletal muscle, nPKCθ, varies with muscle type and in response to fructose-induced insulin resistance. Endocrinology 1994; 135: 2369-2374.
26. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
27. Tesfamariam B, Brown M L, Cohen R A. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J Clin Invest 1991; 87: 1643-1648.
28. Inoguchi T, Battan R, Handler E et al. Preferential elevation of protein kinase C isoform βII and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci 1992; 89: 11059-11063.
29. DeRubertis F R, Craven P A. Activation of protein kinase C in glomerular cells in diabetes: mechanisms and potential links to the pathogenesis of diabetic glomerulopathy. Diabetes 1994; 43: 1-8.
30. Ishii H, Jirousek M R, Koya D et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science 1996; 272: 728-731.
31. Henry R R, Wallace P, Olefsky J M. Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus. Diabetes 1986; 35: 990-998.
32. Zawadski J K, Bogardus C, Foley J E. Insulin action in obese non-insulin-dependent diabetes and in their isolated adipocytes before and after weight loss. Diabetes 1987; 36: 227-236.
33. Singh I. Low fat diet and therapeutic doses of insulin in diabetes mellitus. Lancet 1955; i: 422-425.
34. Kiehm T G, Anderson J W, Ward K. Beneficial effects of a high carbohydrate, high fiber diet on hyperglycemic diabetic men. Am J Clin Nutr 1976; 29: 895-899.
35. Barnard R J, Massey M R, Cherny S et al. Long term use of a high-complex carbohydrate, high fiber, low fat diet and exercise in the treatment of NIDDM patients. Diabetes Care 1983; 6: 268-273.
36. O'Dea K, Traianedes K, Ireland P et al. The effects of diet differing in fat, carbohydrate, and fiber on carbohydrate and lipid metabolism in type II diabetes. J Am Diet Assoc 1989; 89: 1076-1086.
37. Barnard R J, Ugianski E J, Martin D A, Inkeles S B. Role of diet and exercise in the management of hyperinsulinemia and associated atherosclerotic risk factors. Am J Cardiol 1992; 69: 440-444.
38. Fukagawa N K, Anderson J W, Hageman G et al. High-carbohydrate, high-fiber diets increase peripheral insulin sensitivity in healthy young and old adults. Am J Clin Nutr 1990; 52: 524-528.
39. Gumbiner B, Polonsky K S, Beltz W F et al. Effects of weight loss and reduced hyperglycemia on the kinetics of insulin secretion in obese non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab 1990; 70: 1594-1602.
40. McCarty M F. Promotion of hepatic lipid oxidation and gluconeogenesis as a strategy for appetite control. Med Hypotheses 1994; 42: 215-225.
41. McCarty M F. Inhibition of citrate lyase may aid aerobic endurance. Med Hypotheses 1995; 45: 247-254.
42. Kaats G R, Blum K, Fisher J A, Adelman J A. Effects of chromium picolinate supplementation on body composition: a randomized, double-masked, placebo-controlled study. Curr Ther Res 1996; 57: 747-756.
43. Williamson J R, Browning E T, Olson M S. Interrelations between fatty acid oxidation and the control of gluconeogenesis in perfused rat liver. Adv Enzyme Reg 1968; 6: 67-100.
44. Popp-Snijders C, Schouten J A, Heine R J et al. Dietary supplementation of omega-3 polyunsaturated fatty acids improves insulin sensitivity in non-insulin-dependent diabetes. Diabetes Res 1987; 4: 141-147.
45. Willumsen N, Skorve J, Hexeberg S et al. The hypotriglyceridemic effect of eicosapentaenoic acid in rats is reflected in increased mitochondrial fatty acid oxidation followed by diminished lipogenesis. Lipids 1993; 28: 683-690.
46. Glauber H, Wallace P, Griver K, Brechtel G. Adverse metabolic effect of omega-3 fatty acids in non-insulin-dependent diabetes mellitus. Ann Intern Med 1988; 108: 663-668.
47. Stumvoll M, Nurjhan N, Perriello G et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 550-554.
48. Wollen N, Bailey C J. Inhibition of hepatic gluconeogenesis by metformin. Biochem Pharmacol 1988; 37: 4353-4358.
49. Argaud D, Roth H, Weirnsperger N, Leverve X M. Metformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes. Eur J Biochem 1993; 213: 1341-1348.
50. Yu B, Pugazhenthi S, Khandelwal R L. Effects of metformin on glucose and glucagon regulated gluconeogenesis in cultured normal and diabetic hepatocytes. Biochem Pharmacol 1994; 48: 949-954.
51. McCarty M F. A proposal for the locus of metformin's clinical action -potentiation of the activation of pyruvate kinase by fructose- 1,6-diphosphate. Submitted for publication, 1997.
52. Pégorier J-P, Garcia-Garcia M-V, Prip-Buus C et al. Induction of ketogenesis and fatty acid oxidation by glucagon and cyclic AMP in cultured hepatocytes from rabbit fetuses. Biochem J 1989; 264: 93-100.
53. Mabrouk G M, Helmy I M, Thampy K G, Wakil S J. Acute hormonal control of acetyl-coA carboxylase. J Biol Chem 1990; 265: 6330-6338.
54. Geary N, Smith G P. Selective hepatic vagotomy blocks pancreatic glucagon's satiety effect. Physiol Behav 1983; 31: 391-394.
55. Langhans W, Zieger U, Scharrer E, Geary N. Stimulation of feeding in rats by intraperitoneal injection of antibodies to glucagon. Science 1982; 218: 894-896.
56. Shepherd M, Kushwaha R. Effect of metformin on basal and postprandial lipid and carbohydrate metabolism in NIDDM subjects. Diabetes 1994; 43 (Suppl. 1): 74A.
57. Sullivan A C, Triscari J. Possible interrelationship between metabolite flux and appetite. In: Novin D, Wyrwicka W, Bray G, eds. Hunger: Basic Mechanisms and Clinical Implications. New York: Raven Press, 1976: 115-125.
58. Hellerstein M K, Xie Y. The indirect pathway of hepatic glycogen synthesis and reduction of food intake by metabolic inhibitors. Life Sci 1993; 53: 1833-1845.
59. Langhans W, Damaske U, Scharrer E. Different metabolites might reduce food intake by the mitochondrial generation of reducing equivalents. Appetite 1985; 6: 143-152.
60. Langhans W, Egli G, Scharrer E. Regulation of food intake by hepatic oxidative metabolism. Brain Res Bull 1985; 15: 425-428.
61. Langhans W, Scharrer E. Evidence for a vagally mediated satiety signal derived from hepatic fatty acid oxidation. J Auton Nerv Syst 1987; 18: 13-18.
62. Langhans W, Scharrer E. Evidence for a role of the sodium pump of hepatocytes in the control of food intake. J Auton Nerv Syst 1987; 20: 199-205.
63. Rossi R, Geronimi M, Gloor P et al. Hyperpolarization of the cell membrane of mouse hepatocytes by fatty acid oxidation. Physiol Behav 1995; 57: 509-514.
64. 2 and ATP. Am J Physiol 1986; 250: C663-C675.
65. Russek M. Current status of the hepatostatic theory of food intake. Appetite 1981; 2: 137-143/157-162.
66. 2 consumption of isolated rat hepatocytes. Biochim Biophys Acta 1993; 1175: 269-276.
67. Clarke B F, Duncan L J P. Comparison of chlorpropamide and metformin treatment on weight and blood-glucose response of uncontrolled obese diabetics. Lancet 1968; i: 123-126.
68. Clarke B F, Campbell I W. Comparison of metformin and chlorpropamide in non-obese, maturity-onset diabetics uncontrolled by diet. Br Med J 1977; 2: 1576-1578.
69. Lee A, Bray G A. Metformin decreases food consumption in obese non insulin-dependent (NIDDM) diabetics. Diabetes 1996; 45 (Suppl. 2): 170A.
70. Stanko R T, Adibi S A. Inhibition of lipid accumulation and enhancement of energy expenditure by the addition of pyruvate and dihydroxyacetone to a rat diet. Metabolism 1986; 35: 182-186.
71. Cortez M Y, Torgan C E, Brozinick J T Jr et al. Effects of pyruvate and dihydroxyacetone consumption on the growth and metabolic state of obese Zucker rats. Am J Clin Nutr 1991; 53: 847-853.
72. Stanko R T, Tietze D L, Arch J E. Body composition, energy utilization, and nitrogen metabolism with a severely restricted diet supplemented with dihyroxyacetone and pyruvate. Am J Clin Nutr 1992; 55: 771-776.
73. Stanko R T, Tietze D L, Arch J E. Body composition, energy utilization, and nitrogen metabolism with a 4.25-MJ/d low-energy diet supplemented with pyruvate. Am J Clin Nutr 1992; 56: 630-635.
74. Stanko R T, Arch J E. Inhibition of regain in body weight and fat with addition of 3-carbon compounds to the diet with hyperenergetic refeeding after weight reduction. Int J Obesity 1996; 20: 925-930.
75. Pedersen J. The effect of metformin on weight loss in obesity. Acta Endocrinol 1965; 49: 479-486.
76. Munro J F, MacCuish A C, Marshall A et al. Weight-reducing effect of diguanides in obese non-diabetic women. Br Med J 1969; 2: 13-15.
77. Lütjens A, Smit J L J. Effect of biguanide treatment in obese children. Helv Paediat Acta 1976; 31: 473-480.
78. Fontbonne A, Charles M A, Juhan-Vague I et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. Diabetes Care 1996; 19: 920-926.